BamSEC and AlphaSense Join Forces
Learn More

Furiex Pharmaceuticals, Inc.

Formerly NASDAQ: FURX
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 7 pages Joinder to Revenue Rights Purchase Agreement
12/34/56
EX-10.2
from DEFA14A 15 pages Stockholder Voting Agreement
12/34/56
EX-10.2
from 8-K 15 pages Stockholder Voting Agreement
12/34/56
EX-10.1
from DEFA14A 15 pages Form of Cvr Agreement Contingent Value Rights Agreement
12/34/56
EX-10.1
from 8-K 15 pages Form of Cvr Agreement Contingent Value Rights Agreement
12/34/56
EX-10
from 8-K 7 pages First Amended and Restated Employment Agreement
12/34/56
EX-10
from 8-K 16 pages Resignation and Transition Agreement
12/34/56
EX-10
from 8-K 21 pages Pledge Agreement
12/34/56
EX-10
from 8-K 3 pages Secured Promissory Note
12/34/56
EX-10
from 8-K 7 pages Second Omnibus Amendment and Reaffirmation Agreement
12/34/56
EX-10
from 10-Q 15 pages Furiex Pharmaceuticals, Inc. 2010 Stock Plan, as Amended Approved by the Board: March 1, 2013 Approved by the Stockholders: May 24, 2013
12/34/56
EX-10
from 10-Q 6 pages Omnibus Amendment and Reaffirmation Agreement
12/34/56
EX-10.27
from 10-Q 134 pages Priligy License Agreement This License Agreement (Hereinafter Referred to as the “Agreement”) Made and Entered Into as of This May 14, 2012. by and Between Genupro, Inc. a Corporation Organized Under the Laws of the State of North Carolina Having Its Registered Office at 3900 Paramount Parkway, Suite 150 Morrisville, Nc 27560 (Hereinafter Referred to as “Licensor”) and Berlin Chemie AG (Menarini Group) a Corporation Organised Under the Laws of Germany Having Its Registered Office at Glienicker Weg 125, 12489 Berlin Germany
12/34/56
EX-10.26
from 10-Q 139 pages Portions of This Exhibit Marked [*] Are Requested to Be Treated Confidentially. Confidential License and Asset Transfer Agreement by and Between Alza Corporation and Janssen Pharmaceutica, NV and Furiex Pharmaceuticals, Inc., and Genupro, Inc
12/34/56
EX-10.25
from 10-Q 2 pages Secured Promissory Note
12/34/56
EX-10.24
from 10-Q 20 pages Pledge Agreement
12/34/56
EX-10.7
from 8-K 7 pages Consulting Agreement
12/34/56
EX-10.6
from 8-K 20 pages Portions of This Exhibit Marked [*] Have Been Granted Confidential Treatment. Master Development Services Agreement
12/34/56
EX-10.5
from 8-K 11 pages Transition Services Agreement
12/34/56
EX-10.4
from 8-K 12 pages Definitions and Interpretation
12/34/56